[1]梁 新,王亚丽.依达拉奉右莰醇神经保护作用机制及临床应用进展[J].陕西医学杂志,2022,51(2):249-252，封3.[doi:DOI:10.3969/j.issn.1000-7377.2022.02.028]
　LIANG Xin,WANG Yali.Neuroprotective mechanism and clinical application progress of edaravone dexborneol[J].,2022,51(2):249-252，封3.[doi:DOI:10.3969/j.issn.1000-7377.2022.02.028]
点击复制

依达拉奉右莰醇神经保护作用机制及临床应用进展
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年2期
页码:
249-252，封3
栏目:
综 述
出版日期:
2022-02-05

文章信息/Info

Title:
Neuroprotective mechanism and clinical application progress of edaravone dexborneol
作者:
梁 新; 王亚丽
(陕西中医药大学附属医院脑病科,陕西 咸阳 712046)
Author(s):
LIANG Xin; WANG Yali
(Department of Encephalopathy,Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712046,China)
关键词:
依达拉奉右莰醇;  神经保护剂;  缺血性脑卒中;  氧自由基;  神经血管单位;  炎症因子
Keywords:
Edaravone dexborneol;  Neuroprotective agent;  Ischemic stroke;  Oxygen free radical;  Neurovascular unit;  Inflammatory factor
分类号:
R 743.3
DOI:
DOI:10.3969/j.issn.1000-7377.2022.02.028
文献标志码:
A
摘要:
脑卒中是我国成年人致死和致残的首位原因,及时开展溶栓是急性缺血性脑卒中(AIS)的首选方案,但遗憾的是,我国AIS患者溶栓治疗现状不佳。依达拉奉右莰醇是一种新型多靶点神经保护剂,其良好的脑保护作用已得到国内临床研究的证实,为我国AIS患者的治疗带来了新选择。其具有独特的清除自由基、保护神经血管单位和抑制炎症因子、蛋白表达的作用,经Ⅲ期临床研究证实,对比单方依达拉奉注射液,依达拉奉右莰醇疗效优势明显,临床安全性相似,具备更高的临床应用价值。现对依达拉奉右莰醇作用机制及临床应用进展进行综述。
Abstract:
troke is the leading cause of death and disability for adults in China.Thrombolytic therapy is the first choice for acute ischemic stroke(AIS).But unfortunately,the current situation of thrombolytic therapy for patients with AIS in China is not good.Edaravone dexborneol is a new type of multi-target neuroprotective agent,and its good brain protection has been confirmed by domestic clinical studies,which brings a new choice for the treatment of AIS patients in China.It has unique functions of scavenging free radicals,protecting neurovascular units,and inhibiting the expression of inflammatory factors and proteins.Phase Ⅲ clinical studies have confirmed that compared with unilateral edaravone injection,edaravone dexborneol has obvious therapeutic advantages,similar clinical safety and higher clinical application value.In this paper,the neuroprotective mechanism and clinical application progress of edaravone dexborneol are reviewed.

参考文献/References:

[1] 王陇德,刘建民,杨 弋,等.我国脑卒中防治仍面临巨大挑战——《中国脑卒中防治报告2018》概要[J].中国循环杂志,2019,34(2):105-119.
[2] Johnson CO,Nguyen M,Roth GA,et al.Global,regional,and national burden of stroke,1990-2016:A systematic analysis for the global burden of disease study 2016[J].The Lancet Neurology,2019,18(5):439-458.
[3] Kaur H,Prakash A,Medhi B.Drug therapy in stroke:From preclinical to clinical studies[J].Pharmacology,2013,92(5):324-334.
[4] 张颖楠,姜 扬,任 莉,等.依达拉奉右莰醇静脉滴注对急性前循环脑梗死血管内治疗开通良好患者脑损伤的改善作用[J].山东医药,2021,61(18):76-79.
[5] Lin M,Katsumura Y,Hata K,et al.Pulse radiolysis study on free radical scavenger edaravone(3-methyl-1-phenyl-2-pyrazolin-5-one)[J].Journal of Photochemistry and Photobiology B:Biology,2007,89(1):36-43.
[6] Perez-Gonzalez A,Galano A.OH radical scavenging activity of edaravone:Mechanism and kinetics[J].The Journal of Physical Chemistry B,2011,115(5):1306-1314.
[7] 丁宏岩,董 强.自由基清除剂依达拉奉对脑缺血的治疗作用[J].国外医学:脑血管疾病分册,2004,12(7):492-493.
[8] 薛亚妮,刘 瑞,陈 彭,等.依达拉奉注射液联合阿替普酶静脉溶栓治疗急性脑梗死临床疗效观察[J].陕西医学杂志,2021,50(6):731-734.
[9] 刘振宇,王丽华,周俊英.依达拉奉与辛伐他汀配伍治疗脑血管痉挛疗效分析[J].陕西医学杂志,2014,43(4):485-486.
[10] Nishinaka Y,Mori H,Endo N,et al.Edaravone directly reactswith singlet oxygen and protects cells from attack[J].Life Sciences,2010,86(21):808-813.
[11] 王建峰,张晨红,王 婉.缺血性脑血管病相关危险因素分析和治疗后疗效观察[J].陕西医学杂志,2017,46(12):1765-1766.
[12] 高 梅,时丽丽,张恒艾,等.依达拉奉对大鼠急性全脑缺血再灌注损伤的治疗作用[J].中国药学杂志,2011,46(12):932-936.
[13] 江 兴,周玉生,盘 捷,等.依达拉奉作用机制和临床应用研究进展[J].中南药学,2013,11(8):587-592.
[14] Muoio V,Persson PB,Sendeski MM.The neurovascular unit-concept review[J].Acta Physiologica,2014,210(4):790-798.
[15] Steliga A,Kowiański P,Czuba E,et al.Neurovascular unit as a source of ischemic stroke biomarkers:Limitations of experimental studies and perspectives for clinical application[J].Translational Stroke Research,2020,11(4):553-579.
[16] Lee BJ,Egi Y,van Leyen K,et al.Edaravone,a free radical scavenger,protects components of the neurovascular unit against oxidative stress in vitro[J].Brain Research,2010,1307:22-27.
[17] Chen JX,Zhao T,Huang DX.Protective effects of edaravone against cobalt chloride-induced apoptosis in PC12 cells[J].Neuroscience Bulletin,2009,25(2):67-74.
[18] 刘 瑶,刘俊杰,吴寅秋,等.依达拉奉对蛛网膜下腔出血大鼠海马区神经元自噬及凋亡的影响[J].中国老年学杂志,2019,39(2):378-381.
[19] 王 怡,刘俊恒,陈哲俊.依达拉奉对H2O2致星形胶质细胞损伤的保护作用[J].药学与临床研究,2008,13(3):166-169.
[20] 李福泰,姚春虹,慕廷民,等.急性脑梗死患者炎症因子与同型半胱氨酸、纤维蛋白原相关性研究[J].陕西医学杂志,2019,48(1):71-73.
[21] 张建强,焦永平.脉血康胶囊与依达拉奉联合治疗对出血性脑梗死患者血清MMP-9、S100β蛋白水平和神经功能的影响[J].陕西中医,2018,39(11):1521-1523.
[22] Kajdaniuk D,Marek B,Borgiel-Marek H,et al.Vascular endothelial growth factor(VEGF)-part 1:In physiology and pathophysiology[J].Endokrynologia Polska,2011,62(5):444-455.
[23] 黄慧芬,郑丽云,方世记,等.依达拉奉对过氧化氢诱导血管内皮细胞Nrf2/HO-1表达的影响[J].中国临床药学杂志,2017,26(2):88-92.
[24] Lavine SD,Hofman FM,Zlokovic BV.Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury[J].Journal of Cerebral Blood Flow & Metabolism,1998,18(1):52-58.
[25] 王 强,余 丹,梁 霁,等.急性脑梗死患者血浆中AIM2、IL-1β和IL-18的表达及意义[J].中南大学学报:医学版,2021,46(2):149-155.
[26] 赵宏伟.依达拉奉治疗急性脑梗死的临床有效率及对氧化应激和炎症因子的影响研究[J].黑龙江医学,2019,43(6):627-628.
[27] 王拥军,熊云云,杨佳蕾,等.卒中:回眸2020[J].中国卒中杂志,2021,16(2):101-118.
[28] 李 竞,冯宏业,任力杰,等.新型自由基清除剂依达拉奉对急性脑梗死的治疗作用[J].第三军医大学学报,2005,30(7):663-665.
[29] 张 迪,任长虹,吉训明,等.脑缺血-再灌注损伤后的炎性反应过程及机制的研究进展[J].中国脑血管病杂志,2013,10(7):383-387.
[30] Galea J,Brough D.The role of inflammation and interleukin-1 in acute cerebrovascular disease[J].Journal of Inflammation Research,2013,6:121-128.
[31] 王秦川,高 英,王惠霞. 依达拉奉治疗急性脑梗死48例[J].陕西医学杂志,2007,36(8):1053-1055.
[32] 尹德民,魏 钢.醒脑静联合依达拉奉治疗重型颅脑损伤的疗效及对患者血清炎性细胞因子的影响[J].陕西中医,2017,38(11):1519-1520.
[33] 郑笑男,张 铎,李 平.脑出血急性期病理机制的研究进展[J].医学综述,2015,21(16):2947-2950.
[34] 李晓峰.脑出血后继发性脑损伤机制研究进展[J].内科,2015,10(3):383-385.
[35] 尹立国.氧自由基-线粒体信号通路与脑创伤神经细胞死亡以及Edaravone的治疗作用机制研究[D].石家庄:河北医科大学,2007.
[36] Xu J,Wang A,Meng X,et al.Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke:A phase iii,randomized,double-blind,comparative trial[J].Stroke,2021,52(3):772-780.
[37] 张黎宾,封志鹏,陈日升,等.阿替普酶联合依达拉奉右莰醇治疗急性缺血性脑卒中疗效研究[J].智慧健康,2021,7(20):133-135.
[38] Wu HY,Tang Y,Gao LY,et al.The synergetic effect of edaravone and borneol in the rat model of ischemic stroke[J].European Journal of Pharmacology,2014,740(10):522-531.
[39] Xu J,Wang Y,Wang A,et al.Safety and efficacy of edaravone dexborneol versus edaravone for patients with acute ischaemic stroke:A phase II,multicentre,randomised,double-blind,multiple-dose,active-controlled clinical trial[J].Stroke and Vascular Neurology,2019,4(3):109-114.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(30973829)
更新日期/Last Update: 2022-02-09